120 related articles for article (PubMed ID: 16011415)
1. Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
Noguera Aguilar JF; Amengual Antich I; Morón Canis JM; Plaza Martínez A; Martínez Córcoles JA; Tortajada Collado C; Pujol Tugores JJ
Rev Esp Enferm Dig; 2005 Jun; 97(6):405-15. PubMed ID: 16011415
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Noguera Aguilar JF; Amengual Antich I; Plaza Martínez A; Ibarra de la Rosa J; Tortajada Collado C; Gamundí Gamundí A; Pujol Tugores JJ
Rev Esp Enferm Dig; 2005 Sep; 97(9):637-47. PubMed ID: 16266236
[TBL] [Abstract][Full Text] [Related]
3. Influence of rofecoxib on experimental colonic carcinogenesis in rats.
Noguera Aguilar JF; Plaza Martínez A; Amengual Antich I; Morón Canis JM; Tortajada Collado C; Pujol Tugores JJ
Rev Esp Enferm Dig; 2004 Oct; 96(10):678-82; 683-6. PubMed ID: 15537374
[TBL] [Abstract][Full Text] [Related]
4. JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
Wei M; Morimura K; Wanibuchi H; Shen J; Salim EI; Moku M; Hakoi K; Fukushima S
Int J Cancer; 2005 Jan; 113(3):354-8. PubMed ID: 15455344
[TBL] [Abstract][Full Text] [Related]
5. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib.
Kubatka P; Ahlers I; Ahlersová E; Adámeková E; Luk P; Bojková B; Marková M
Cancer Lett; 2003 Dec; 202(2):131-6. PubMed ID: 14643442
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
Fei SJ; Xiao SD; Peng YS; Chen XY; Shi Y
Chin J Dig Dis; 2006; 7(3):134-40. PubMed ID: 16808793
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive response of diclofenac, a non-steroidal anti-inflammatory drug in experimental carcinogenesis.
Kaur Saini M; Kaur J; Sharma P; Nath Sanyal S
Nutr Hosp; 2009; 24(6):717-23. PubMed ID: 20049376
[TBL] [Abstract][Full Text] [Related]
11. Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model.
Sharma P; Kaur J; Sanyal SN
Nutr Hosp; 2010; 25(1):39-48. PubMed ID: 20204254
[TBL] [Abstract][Full Text] [Related]
12. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Evans JF
Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib as adjunctive therapy for haemophilic arthropathy.
Rattray B; Nugent DJ; Young G
Haemophilia; 2005 May; 11(3):240-4. PubMed ID: 15876269
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
Kivitz AJ; Greenwald MW; Cohen SB; Polis AB; Najarian DK; Dixon ME; Moidel RA; Green JA; Baraf HS; Petruschke RA; Matsumoto AK; Geba GP;
J Am Geriatr Soc; 2004 May; 52(5):666-74. PubMed ID: 15086644
[TBL] [Abstract][Full Text] [Related]
17. [Prescribing patterns of rofecoxib in the primary care setting: results of a French survey].
Bannwarth B; Logeart I; Vergult G
Rev Med Interne; 2004 Oct; 25(10):710-4. PubMed ID: 15471596
[TBL] [Abstract][Full Text] [Related]
18. Perianastomotic colonic tumors after inclusion of titanium or Lactomer in the anastomotic suture line. An experimental study in rats.
Noguera Aguilar JF; Zurita Romero M; Tortajada Collado C; Amengual Antich I; Soro Gosálvez JA; Rial Planas R
Rev Esp Enferm Dig; 2000 Jan; 92(1):36-43. PubMed ID: 10749596
[TBL] [Abstract][Full Text] [Related]
19. Colonic perianastomotic carcinogenesis in an experimental model.
Pérez-Holanda S; Rodrigo L; Pinyol-Felis C; Vinyas-Salas J
BMC Cancer; 2008 Jul; 8():217. PubMed ID: 18667092
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
